These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36746323)

  • 1. Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies.
    Avila AM; Bebenek I; Mendrick DL; Peretz J; Yao J; Brown PC
    Regul Toxicol Pharmacol; 2023 Mar; 139():105345. PubMed ID: 36746323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs).
    Avila AM; Bebenek I; Bonzo JA; Bourcier T; Davis Bruno KL; Carlson DB; Dubinion J; Elayan I; Harrouk W; Lee SL; Mendrick DL; Merrill JC; Peretz J; Place E; Saulnier M; Wange RL; Yao J; Zhao D; Brown PC
    Regul Toxicol Pharmacol; 2020 Jul; 114():104662. PubMed ID: 32325112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment.
    Turner J; Pound P; Owen C; Hutchinson I; Hop M; Chau DYS; Barrios Silva LV; Coleman M; Dubourg A; Harries LW; Hutter V; Kenna JG; Lauschke VM; Neuhaus W; Roper C; Watkins PB; Welch J; Alvarez LR; Taylor K
    ALTEX; 2023; 40(3):519-533. PubMed ID: 36692187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond pharmaceuticals: Fit-for-purpose new approach methodologies for environmental cardiotoxicity testing.
    Daley MC; Mende U; Choi BR; McMullen PD; Coulombe KLK
    ALTEX; 2023; 40(1):103-116. PubMed ID: 35648122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Affecting the Perception of New Approach Methodologies (NAMs) in the Ecotoxicology Community.
    Mondou M; Hickey GM; Rahman HT; Maguire S; Pain G; Crump D; Hecker M; Basu N
    Integr Environ Assess Manag; 2020 Mar; 16(2):269-281. PubMed ID: 31944596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerating the Pace of Chemical Risk Assessment.
    Kavlock RJ; Bahadori T; Barton-Maclaren TS; Gwinn MR; Rasenberg M; Thomas RS
    Chem Res Toxicol; 2018 May; 31(5):287-290. PubMed ID: 29600706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of New Approach Methodologies (NAMs) in regulatory decisions for chemical safety: Report from an EPAA Deep Dive Workshop.
    Westmoreland C; Bender HJ; Doe JE; Jacobs MN; Kass GEN; Madia F; Mahony C; Manou I; Maxwell G; Prieto P; Roggeband R; Sobanski T; Schütte K; Worth AP; Zvonar Z; Cronin MTD
    Regul Toxicol Pharmacol; 2022 Nov; 135():105261. PubMed ID: 36103951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brazil's Regulatory Context for Using New Approach Methodologies (NAMs) on the Registration of Products.
    Villela IV; Machado MDS
    Front Toxicol; 2022; 4():903027. PubMed ID: 35936389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing food safety risk assessment in China: development of new approach methodologies (NAMs).
    Yang D; Yang H; Shi M; Jia X; Sui H; Liu Z; Wu Y
    Front Toxicol; 2023; 5():1292373. PubMed ID: 38046399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing New Approach Methodologies (NAMs) for Tobacco Harm Reduction: Synopsis from the 2021 CORESTA SSPT-NAMs Symposium.
    Lee KM; Corley R; Jarabek AM; Kleinstreuer N; Paini A; Stucki AO; Bell S
    Toxics; 2022 Dec; 10(12):. PubMed ID: 36548593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity testing is evolving!
    Fischer I; Milton C; Wallace H
    Toxicol Res (Camb); 2020 Apr; 9(2):67-80. PubMed ID: 32440338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of the First ONTOX Stakeholder Network Meeting: Digging Under the Surface of ONTOX Together With the Stakeholders.
    Diemar MG; Vinken M; Teunis M; Krul CAM; Busquet F; Zajac JD; Kandarova H; Corvi R; Rosso MZ; Kharina A; Bryndum LS; Santillo M; Bloch D; Kucheryavenko O; Panagiotakos D; Rogiers V; Beekhuijzen M; Giusti A; Najjar A; Courage C; Koenig T; Kolle S; Boonen H; Dhalluin S; Boberg J; Müller BP; Kukic P; Ritskes-Hoitinga M; Grasselli E; Zietek T; Stoddart G; Heusinkveld HJ; Castell JV; Benfenati E; Yang H; Perera S; Paini A; Kramer NI; Hartung T; Janssen M; Fritsche E; Jennen DGJ; Piumatti M; Rathman J; Marusczyk J; Milec L; Roggen EL
    Altern Lab Anim; 2024 Mar; 52(2):117-131. PubMed ID: 38235727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualification of cardiac troponins for nonclinical use: a regulatory perspective.
    Hausner EA; Hicks KA; Leighton JK; Szarfman A; Thompson AM; Harlow P
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):108-14. PubMed ID: 23876748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities.
    Tyner KM; Zheng N; Choi S; Xu X; Zou P; Jiang W; Guo C; Cruz CN
    AAPS J; 2017 Jul; 19(4):1071-1083. PubMed ID: 28421428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of new approach methodologies (NAMs) to meet regulatory requirements for the assessment of tobacco and other nicotine-containing products.
    Miller-Holt J; Behrsing HP; Clippinger AJ; Hirn C; Stedeford TJ; Stucki AO
    Front Toxicol; 2022; 4():943358. PubMed ID: 36157974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Workgroup report: Review of genomics data based on experience with mock submissions--view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee.
    Leighton JK; Brown P; Ellis A; Harlow P; Harrouk W; Pine PS; Robison T; Rosario L; Thompson K
    Environ Health Perspect; 2006 Apr; 114(4):573-8. PubMed ID: 16581548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of new approach methodologies (NAMs) to meet regulatory requirements for the assessment of industrial chemicals and pesticides for effects on human health.
    Stucki AO; Barton-Maclaren TS; Bhuller Y; Henriquez JE; Henry TR; Hirn C; Miller-Holt J; Nagy EG; Perron MM; Ratzlaff DE; Stedeford TJ; Clippinger AJ
    Front Toxicol; 2022; 4():964553. PubMed ID: 36119357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies.
    Moffit JS; Blanset DL; Lynch JL; MacLachlan TK; Meyer KE; Ponce R; Whiteley LO
    Hum Gene Ther; 2022 Nov; 33(21-22):1126-1141. PubMed ID: 35994386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approach methodologies in human regulatory toxicology - Not if, but how and when!
    Schmeisser S; Miccoli A; von Bergen M; Berggren E; Braeuning A; Busch W; Desaintes C; Gourmelon A; Grafström R; Harrill J; Hartung T; Herzler M; Kass GEN; Kleinstreuer N; Leist M; Luijten M; Marx-Stoelting P; Poetz O; van Ravenzwaay B; Roggeband R; Rogiers V; Roth A; Sanders P; Thomas RS; Marie Vinggaard A; Vinken M; van de Water B; Luch A; Tralau T
    Environ Int; 2023 Aug; 178():108082. PubMed ID: 37422975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.